sales@angenesci.com
Login | Register
logo
Structures Search
Home Sulfos N-(6-(3-(tert-Butyl)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide

N-(6-(3-(tert-Butyl)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide

CAS No.:
1132935-63-7
Catalog Number:
AG008TD8
Molecular Formula:
C26H27N3O5S
Molecular Weight:
493.5747
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
5mg
95%
In Stock USA
United States
$68
- +
10mg
95%
In Stock USA
United States
$107
- +
25mg
95%
In Stock USA
United States
$214
- +
50mg
95%
In Stock USA
United States
$287
- +
100mg
95%
In Stock USA
United States
$485
- +
Product Description
Catalog Number:
AG008TD8
Chemical Name:
N-(6-(3-(tert-Butyl)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide
CAS Number:
1132935-63-7
Molecular Formula:
C26H27N3O5S
Molecular Weight:
493.5747
MDL Number:
MFCD27923655
IUPAC Name:
N-[6-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]naphthalen-2-yl]methanesulfonamide
InChI:
InChI=1S/C26H27N3O5S/c1-26(2,3)22-15-20(29-11-10-23(30)27-25(29)31)14-21(24(22)34-4)18-7-6-17-13-19(28-35(5,32)33)9-8-16(17)12-18/h6-15,28H,1-5H3,(H,27,30,31)
InChI Key:
NBRBXGKOEOGLOI-UHFFFAOYSA-N
SMILES:
COc1c(cc(cc1C(C)(C)C)n1ccc(=O)[nH]c1=O)c1ccc2c(c1)ccc(c2)NS(=O)(=O)C
UNII:
DE54EQW8T1
Properties
Complexity:
938  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
493.167g/mol
Formal Charge:
0
Heavy Atom Count:
35  
Hydrogen Bond Acceptor Count:
6  
Hydrogen Bond Donor Count:
2  
Isotope Atom Count:
0
Molecular Weight:
493.578g/mol
Monoisotopic Mass:
493.167g/mol
Rotatable Bond Count:
6  
Topological Polar Surface Area:
113A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
4.3  
Literature
Title Journal
Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use. Drugs 20170701
Metabolism and Disposition of Hepatitis C Polymerase Inhibitor Dasabuvir in Humans. Drug metabolism and disposition: the biological fate of chemicals 20160801
Dasabuvir (ABT333) for the treatment of chronic HCV genotype I: a new face of cure, an expert review. Expert review of anti-infective therapy 20160101
New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir. Expert review of clinical pharmacology 20160101
Interferon-free therapy for hepatitis C: The hurdles amid a golden era. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20150901
Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection. The Annals of pharmacotherapy 20150501
Dasabuvir : a new direct antiviral agent for the treatment of hepatitis C. Expert opinion on pharmacotherapy 20150301
An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Canadian journal of gastroenterology & hepatology 20150101
Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A. Journal of medicinal chemistry 20140313
Dasabuvir: A Non-Nucleoside Inhibitor of NS5B for the Treatment of Hepatitis C Virus Infection. Reviews on recent clinical trials 20140101
Properties